Article and Video CATEGORIES

Cancer Journey

Search By

Lung Cancer Video Library - Zoledronate or Denosumab for Lung Cancer with Bone Metastases
Fri, 04/01/2016 - 06:00
Author
GRACE Videos and Articles
Image
 

Transcript

One of the important points about patients with advanced lung cancer is that 30-40% of patients will develop bone metastases. I think it’s important to recognize this is not bone cancer, this is lung cancer that’s moved to the bone, and in 30-40% of patients at some point who have advanced stage lung cancer, they will develop bone metastases. The question is: how do you manage these patients?

Now of course they’re going to be treated with chemotherapy or targeted therapies or immunotherapies to help control the cancer, but one of the other strategies that’s employed are bone strengthening agents. They come in really two forms, and the goals of giving a bone strengthening agent really are to delay skeletal-related events or fractures, and also strengthen the bones. I would say that they’re the standard of care for any patient with lung cancer who has bone metastases.

So currently there are two approved drugs for lung cancer patients with bone metastases. The first is called zoledronic acid, it’s given every three weeks and it’s a class of drugs called a bisphosphonate. These drugs are also used for osteoporosis. What we know about zoledronic acid or Zometa is that it does delay skeletal-related events or fractures in patients who get these drugs who have bone metastases in lung cancer.

The second class of drugs are called RANK-Ligand inhibitors, and the drug that’s approved for lung cancer is denosumab or Xgeva. This drug is a little different in its administration — it’s given subcutaneously rather than intravenously, and it’s also given every four weeks rather than every three weeks.

I think what we know about both of these drugs is that they do help strengthen the bones and delay skeletal-related events, but there’s a hint that denosumab, that second drug I mentioned, may also have some sort of anti-tumor effect. I’m not sure that this is completely ironed out in the literature, but we do know at least in one study published in 2012 that patients who actually got denosumab as a bone strengthening agent actually lived longer than those patients who got zoledronic acid. Now whether we can make or glean any major messages from this, I’m not sure. Nevertheless, my practice has been that any patient with lung cancer who develops bone metastases needs to be put on one of these two drugs.

These drugs do have side effects — one of the side effects with zoledronic acid is osteonecrosis of the jaw. This has happened in a very, very small percentage of patients so I don’t think that’s enough of a concern for me not to use the drug. Both of these drugs are extremely well tolerated and actually do help with the end points that I mentioned in terms of delaying fracture for those patients with bone metastases, but also potentially improving outcomes specifically with denosumab.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29